Clinical trials: Experimental

Lymphoblastic Leukemia, Acute Adult

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

• Active, not recruiting
• Age: 16 years and older
• Phase 1/2
• Injection or infusion

Evaluate the safety (P-I), pharmacokinetics and anti-tumor effect of immunotherapy of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR) (TBI-1501) for relapsed or refractory CD19+ B-cell…

Trial name

TBI-1501 (NCT03155191)

Testing

TBI-1501

Where

11 sites in Japan

Volunteers

21 people

Sponsor

Takara Bio Inc.